Our Services
Medical Information
Helpful Resources
Published on: 4/5/2026
Zofran can be effective for severe morning sickness and hyperemesis gravidarum when B6, doxylamine, and dietary measures fail, with large studies showing no major increase in overall birth defects but a small possible rise in specific risks such as certain heart defects or oral clefts, particularly with first trimester use; absolute risks appear low.
There are several factors to consider. See below for detailed benefits, risks, fetal safety data, timing and dosing considerations, maternal side effects like QT prolongation, red flags that need urgent care, and how to discuss the right next steps with your clinician.
Severe morning sickness can be physically and emotionally exhausting. For some pregnant women, nausea and vomiting go far beyond the typical early pregnancy symptoms. When symptoms become intense or persistent, doctors may prescribe Zofran (generic name: ondansetron).
Zofran was originally developed to prevent nausea and vomiting caused by chemotherapy and surgery. Over time, it has also been used "off-label" during pregnancy to treat severe nausea and vomiting, especially when other treatments have not worked.
This article explains the benefits, risks, and fetal safety data around Zofran so you can have an informed discussion with your healthcare provider.
Most pregnant women experience some nausea during the first trimester. However, about 0.5% to 2% develop Hyperemesis Gravidarum (HG) — a severe form of pregnancy-related nausea and vomiting that may require medical intervention.
Hyperemesis gravidarum can cause:
Severe nausea and vomiting during pregnancy is not just uncomfortable — it can become medically serious if untreated.
Zofran (ondansetron) works by blocking serotonin (5-HT3) receptors in the brain and gut. Serotonin is one of the chemicals involved in triggering nausea and vomiting.
By blocking these signals, Zofran can:
It is available as:
Zofran is generally not considered first-line treatment for mild morning sickness.
Professional medical organizations typically recommend starting with:
If these treatments fail and symptoms remain severe, a doctor may consider other anti-nausea medications, including Zofran.
Zofran is more commonly considered when:
The decision to prescribe Zofran is usually based on balancing maternal health risks against possible fetal risks.
For many women with severe symptoms, Zofran can provide meaningful relief.
Untreated hyperemesis gravidarum itself carries risks, including:
In severe cases, the benefits of controlling vomiting may outweigh potential medication risks.
The safety of Zofran during pregnancy has been studied extensively, but findings have been somewhat mixed. Here is what credible research suggests:
Large observational studies involving hundreds of thousands of pregnancies have generally found:
This is reassuring overall.
Some studies have suggested a small increased risk of certain heart defects, particularly when Zofran is used in the first trimester. However:
A few studies have reported a small increase in oral clefts (such as cleft palate), particularly with first-trimester use. Again:
Most large studies have not found a consistent increase in:
It's important not to confuse relative risk with absolute risk.
For example:
That means the vast majority of pregnancies are still unaffected.
Your doctor can help interpret what those numbers mean for your personal situation.
Like any medication, Zofran has potential side effects.
Patients with certain heart conditions or those taking other QT-prolonging medications may need closer monitoring.
The first trimester is when major organs develop, so medication exposure during this time receives extra scrutiny.
If possible, doctors may:
However, severe dehydration and malnutrition in early pregnancy also carry risks. This is why treatment decisions must be individualized.
When considering Zofran, your doctor will assess:
In many cases of severe hyperemesis gravidarum, the benefit of stabilizing the mother may outweigh the small potential increase in fetal risk.
No medication is completely risk-free — but neither is untreated severe illness.
If you are prescribed Zofran:
If you experience:
Seek medical care promptly. Severe dehydration can become dangerous quickly.
You should speak to a doctor right away if you have:
Anything that could be serious or life-threatening requires urgent medical attention.
Zofran can be an effective treatment for severe morning sickness and hyperemesis gravidarum, especially when other treatments fail.
Current research suggests:
The decision to use Zofran is highly personal and should be made in partnership with your healthcare provider.
If your nausea and vomiting feel overwhelming, don't ignore it. Severe symptoms deserve medical attention. If you're experiencing persistent vomiting, significant weight loss, or dehydration, use Ubie's free AI-powered Hyperemesis Gravidarum symptom checker to better understand your symptoms before your next doctor's appointment.
Most importantly, speak to a qualified healthcare professional before starting or stopping Zofran. Only your doctor can assess your individual risk and determine what is safest for both you and your baby.
You do not have to suffer in silence — help is available, and treatment decisions can be made thoughtfully and safely.
(References)
* Clark SM, Rémillard F, Okun N, Einarson A, Koren G. Ondansetron for nausea and vomiting in pregnancy: a systematic review and meta-analysis. Birth Defects Res. 2018 Feb;110(2):162-175. doi: 10.1002/bdr2.1130. Epub 2018 Jan 13. PMID: 29334812.
* Kaplan YC, Keskin-Arslan Z, Acar S, Sozmen EY. Ondansetron in pregnancy: A critical appraisal of reported fetal outcomes. Reprod Toxicol. 2017 Aug;72:143-149. doi: 10.1016/j.reprotox.2017.06.007. Epub 2017 Jun 14. PMID: 28624641.
* Huybrechts KF, Hernández-Díaz S, Straub L, Maurer D, Bateman BT, Cohen LS, Mogun H, Hoban RA, Mogielnicki A, Choudhry NK, Desai RJ. Ondansetron and the Risk of Congenital Malformations: A Systematic Review and Meta-analysis. JAMA Pediatr. 2016 Jan;170(1):45-53. doi: 10.1001/jamapediatrics.2015.3340. PMID: 26551065.
* Carstairs SD. Ondansetron in Pregnancy: Evidence of Safety and Clinical Implications. Drugs. 2018 Jul;78(10):971-981. doi: 10.1007/s40265-018-0925-5. PMID: 29892803.
* Lavecchia M, Saccardo F, Benhamou D, Montanari C, Malek E, Gouliez A, Le Duff F, Defrance V, Thiebaugeorges O, Robert G. Safety of ondansetron in pregnancy: a systematic review and meta-analysis. PLoS One. 2017 Jul 18;12(7):e0181513. doi: 10.1371/journal.pone.0181513. PMID: 28719602; PMCID: PMC5515437.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.